<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200820048466N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-09-13</date_registration>
      <primary_sponsor>Arak University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of ice pack and lidocaine ointment in the pain of subcutaneous enoxaparin injection</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of ice pack and lidocaine ointment in the pain of subcutaneous enoxaparin injection</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-09-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>108</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/50469</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Other, Purpose: Prevention, Randomization description: In this study, 108 heart patients were selected according to the inclusion criteria and by available sampling and block random allocation, by assigning the letter A to the ice pack group, the letter B to the lidocaine group and the letter C to the control group in six cases. ABC, ACB, BAC, BCA, CAB, CBA are written on separate sheets and thrown into a container and one of the sheets is randomly taken out of the container and the composition written on it is written down and again. That sheet is thrown into the container. Because the sample size in this study is 108 patients, this operation should be repeated 36 times. Each time the composition written on each sheet is written in the sequence written on the previous sheet. Then, for each letter, a number from one to one hundred and eight is assigned to the letters written in sequence, and each letter is placed in an envelope and the letter number is written on the envelope. Each time a patient is selected, one of the envelopes is opened in the order written on the envelope and it is determined that the patient should be in intervention group 1, 2 or 3, they are divided into three groups, Blinding description: In this study,to avoid bias,the use of ice packs and lidocaine ointment and enoxaparin injection is performed by one person in the group and is measured by another person in the group.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Pain due to Enoxaparin injection.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group : group 1 patients undergo ice bag intervention. one minute before the injection, the ice pack is placed on the site where the enoxaparin is to be performed. immediately after removing the ice pack, the injection site is disinfected in the usual way using normal saline and subcutaneous injection is performed by one person in both groups, immediately after the injection of the patients pain with VAS instrument measured and recorded. Intervention 2: Intervention group: Group 2 patients underwent the intervention with 5% lidocaine ointment. 2 g equals 15 cm (from 5% lidocaine ointment tube weighing 15 g) was measured with a Scaltec laboratory scale with an accuracy of 0.01 g. After performing several measurements under the same conditions, the length of the ointment used was calculated to be 15 cm. Apply lidocaine on the calibrated pad and place it on the stand. After 30 minutes, the ointment is removed from the stand. Using a checklist, the possible side effects of lidocaine ointment are investigated and recorded. Side effects of topical lidocaine include redness and irritation of the lidocaine ointment . Using a normal saline impregnated pad, the injection site is cleansed and the subcutaneous injection is performed by one person in each of the three groups. Immediately after the injection, the patient's pain is measured and recorded with a VAS instrument. Intervention 3: Control group: The control group did not perform any intervention and immediately after injection, the patient's pain was measured and recorded with a VAS instrument.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Article

When:
2020

To whom:
researchers

Conditions:
reseachers

Where to obtain:
fshahivand93@yahoo.com

How to obtain:
email
fshahivand93@yahoo.com

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fereydoun Shahivand</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Sardasht Square</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3848176941</zip>
        <telephone>+98 86 3417 3524</telephone>
        <email>amoozesh@arakmu.ac.ir</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fereydoun Shahivand</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Sardasht Square</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3848176941</zip>
        <telephone>+98 86 3417 3524</telephone>
        <email>amoozesh@arakmu.ac.ir</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age 30-65 years
Awareness
Ability to communicate and answer questions and show the amount of pain
Stability of the clinical condition
No drug addiction
No history of allergies to local anesthetics
No known mental illness</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Canceling
Discharge
Transfer
Patient death</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group : group 1 patients undergo ice bag intervention. one minute before the injection, the ice pack is placed on the site where the enoxaparin is to be performed. immediately after removing the ice pack, the injection site is disinfected in the usual way using normal saline and subcutaneous injection is performed by one person in both groups, immediately after the injection of the patients pain with VAS instrument measured and recorded.</i_keyword>
      <i_keyword>Intervention group: Group 2 patients underwent the intervention with 5% lidocaine ointment. 2 g equals 15 cm (from 5% lidocaine ointment tube weighing 15 g) was measured with a Scaltec laboratory scale with an accuracy of 0.01 g. After performing several measurements under the same conditions, the length of the ointment used was calculated to be 15 cm. Apply lidocaine on the calibrated pad and place it on the stand. After 30 minutes, the ointment is removed from the stand. Using a checklist, the possible side effects of lidocaine ointment are investigated and recorded. Side effects of topical lidocaine include redness and irritation of the lidocaine ointment . Using a normal saline impregnated pad, the injection site is cleansed and the subcutaneous injection is performed by one person in each of the three groups. Immediately after the injection, the patient's pain is measured and recorded with a VAS instrument.</i_keyword>
      <i_keyword>Control group: The control group did not perform any intervention and immediately after injection, the patient's pain was measured and recorded with a VAS instrument</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Patient pain rate with VAS instrument. Timepoint: Immediately after injection. Method of measurement: Visual Analogue Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Pain Rate. Timepoint: Immediately. Method of measurement: VAS.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Arak University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-06-28</approval_date>
        <contact_name>Ethics committee of Arak university of medicine</contact_name>
        <contact_address>Sardasht Square Arak Markazi Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
